Overview

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This research is studying the effect of the combination of how two study drugs (Nivolumab and DKN-01) works in people with advanced biliary tract cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Bristol-Myers Squibb
Leap Therapeutics, Inc.
Treatments:
Nivolumab